Biogen spent a majority of its lengthy second-quarter earnings conference call Tuesday emphasizing a shift to a more aggressive clinical research and business development strategy in neuroscience.
The Biogen plan, neatly summarized: Use cash flow from its existing multiple sclerosis business to expand the company’s neuroscience portfolio and fuel future earnings growth. Boring share repurchases are out. What’s in? Sexy acquisitions and/or partnering deals to bring in new drugs targeting Alzheimer’s, Parkinson’s, spinal muscular atrophy, neuromuscular disorders, and other neuroscience diseases.
About the Author Reprints
Adam, good list. I would include Acadia with pimavanserin on this list.
No exciting science but some decent revenue opportunities for CNS formulation cos like Adamas and Supernus, maybe Corium. Remembering Avanir/Otsuka.